PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02326805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

NIH

Sponsor class

Conditions

Stage I Prostate Adenocarcinoma AJCC v7
Stage II Prostate Adenocarcinoma AJCC v7

Interventions

OTHER: Laboratory Biomarker Analysis
OTHER: Placebo Administration
BIOLOGICAL: Rilimogene Galvacirepvec

Sponsor

National Cancer Institute (NCI)